Investing.com - Proteostasis Therapeutics reported on Monday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Proteostasis Therapeutics announced earnings per share of $-0.31 on revenue of $1.4M. Analysts polled by Investing.com EPS of $-1.08 on revenue of $2.5M.
Proteostasis Therapeutics 's are down 67% and is trading at $1.75 , still down 67.26% from its 52 week high of $5.34 set on Monday, November 15, 2021.
Proteostasis Therapeutics follows other major Healthcare sector earnings this month
Proteostasis Therapeutics's report follows an earnings beat by J&J on Tuesday, October 18, 2022, who reported EPS of $2.55 on revenue of $23.79B, EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on Tuesday, November 1, 2022 with third quarter EPS of $1.98 on revenue of $6.94B, for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar